Relapsing Multiple Sclerosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Relapsing Multiple Sclerosis Market Outlook
Thelansis’s “Relapsing Multiple
Sclerosis Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Relapsing Multiple Sclerosis
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Relapsing Multiple Sclerosis Overview
Relapses,
which are episodic exacerbations of neurological signs or symptoms, constitute
a defining aspect of relapsing-remitting multiple sclerosis (MS), the most
prevalent phenotype within the spectrum of MS. These relapses primarily
contribute to the diagnostic criteria for clinically definite MS, while their
prognostic significance stems from their tendency to result in incomplete
remission and subsequent residual disability. Although the underlying
mechanisms governing the occurrence of relapses remain unidentified, a range of
factors that modify the risk of relapse has been identified. These factors
encompass demographic and clinical attributes, many of which offer
opportunities for enhancing disease management. Furthermore, the specific
patterns of relapse have been linked to patient and disease characteristics,
suggesting that a person’s predisposition to certain phenotypic manifestations
might indicate distinct neuroanatomical disease patterns. Immunomodulatory
therapies and corticosteroids are the primary strategies for preventing
relapses and managing acute episodes.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment